In last six months, after assuming the tenure track investigator position, I have been working on establishing a pancreatic cancer research program in the laboratory. We have initiated the large-scale mRNA and microRNA (miRNA) expression analysis of 25 pancreatic ductal adenocarcinoma (PDAC) samples and paired surrounding non-tumorous pancreas from the patients with epidemiological profile and 3 normal pancreas from non-cancer donors that have been collected through the NCI-University of Maryland Resource Contract. We also have obtained a set of 40 PDAC samples from collaborators in Germany. The two sets of samples are being used as test and validation cohorts in our studies to identify novel biomarkers for the disease. We are currently preparing a protocol and questionnaire to initiate the case-control study of pancreatic cancer in the greater Baltimore area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011162-01
Application #
7966134
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2009
Total Cost
$253,888
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Wang, Jian; Hussain, S Perwez (2017) NO(•) and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. Antioxid Redox Signal 26:1000-1008
Wang, Jian; Yang, Shouhui; He, Peijun et al. (2016) Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Clin Cancer Res 22:5992-6001
Hussain, S Perwez (2016) Pancreatic Cancer: Current Progress and Future Challenges. Int J Biol Sci 12:270-2
Budhu, Anuradha; Terunuma, Atsushi; Zhang, Geng et al. (2014) Metabolic profiles are principally different between cancers of the liver, pancreas and breast. Int J Biol Sci 10:966-72
Zhang, Geng; He, Peijun; Tan, Hanson et al. (2013) Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 19:4983-93
Zhang, Geng; He, Peijun; Gaedcke, Jochen et al. (2013) FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res 73:5416-25
Zhang, Geng; Schetter, Aaron; He, Peijun et al. (2012) DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One 7:e31507